New hope for tough cancers: scientists test Triple-Threat drug cocktail in kids
NCT ID NCT02389309
Summary
This early-stage trial is testing a new combination of three drugs—dasatinib, temsirolimus, and cyclophosphamide—to treat advanced solid tumors that have come back or stopped responding to other treatments. The main goal is to find the safest dose and understand the side effects. The study is for children and young adults (ages 1-21) whose cancer has progressed despite standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.